- Redwire (RDW, Financial) launches new Industrial Crystallizer with 200x processing capacity for in-space drug development.
- The 'Golden Balls' experiment will attempt to produce gold nanospheres in space, enhancing cancer detection and treatment.
- New technologies were launched aboard SpaceX's 32nd commercial resupply mission to the ISS.
Redwire Corporation (RDW) has expanded its in-space pharmaceutical program with the introduction of innovative drug development technology and a groundbreaking cancer-detection experiment aboard the International Space Station (ISS). The company has launched a high-volume Industrial Crystallizer capable of processing samples up to 200 times the volume of its predecessor, the PIL-BOX technology, allowing for scale-up towards commercial applications.
The focus of this mission is the 'Golden Balls' experiment, which aims to produce gold nanospheres in space for the first time. These nanospheres are poised to revolutionize cancer detection and treatment by enhancing size consistency and surface structure quality, which are challenging to achieve on Earth. John Vellinger, President of Redwire's In-Space Industries, emphasized that these advancements could lead to more accurate blood tests and improved therapies for cancer.
This ambitious venture was launched on April 21st aboard SpaceX's 32nd commercial resupply mission to the ISS. By leveraging the unique conditions of microgravity, Redwire seeks to bridge the gap between experimental research and commercial viability, potentially unlocking new pathways for advanced diagnostics and treatments.
